A study on the pharmacokinetics and repeatability of [18F]Fluoromethylcholine PET-CT in patients with prostate cancer

Completed

• Conditions: prostate cancer; prostate malignancy; 10027656

• Registration Number: NL-OMON39240
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Part A:
1. Histologically proven metastasised prostate cancer
2. Written informed consent
3. At least 2 tumours (metastases) per patient detected by conventional imaging (e.g., bone scan, CT or MRI of the chest, abdomen or pelvic region); conventional imaging should be recently performed (no longer than 3 months previous to the PET-CT scan)
4. At least one tumour (metastasis) with a diameter equal or more than 1.5 cm (to minimize partial volume effects)
5. Patients able to remain supine for 50 minutes in the PET-CT scanner
Part B:
1. Histologically proven metastasised prostate cancer
2. Written informed consent
3. At least one tumour (metastasis) with a diameter equal or more than 1.5 cm detected by recently performed conventional imaging (maximal 3 months prior to the PET-CT scan)
4. Patients able to remain supine for 60 minutes in the PET-CT scanner

Exclusion Criteria

1. Claustrophobia (part A and B);
2. Multiple malignancies (part A and B);
3. Anticoagulant therapy (part A).

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Part A: A pharmacokinetic model for [18F]FCH and an appropriate simplified<br /><br>quantitative method.<br /><br><br /><br>Part B: Test-retest variability of the simplified method of choice (part A)<br /><br>implemented in WB [18F]FCH PET-CT.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To identify an appropriate simplified quantitative method for clinical<br /><br>practice. </p><br>